JELÍNKOVÁ, Šárka, Aleksandra VILOTIĆ, Jan PŘIBYL, Franck AIMOND, Anton SALYKIN, Ivana AĆIMOVIĆ, Martin PEŠL, Guido CALUORI, Šimon KLIMOVIČ, Tomáš URBAN, Hana DOBROVOLNÁ, Vladimír SOŠKA, Petr SKLÁDAL, Alain LACAMPAGNE, Petr DVOŘÁK, Albano C. MELI and Vladimír ROTREKL. DMD Pluripotent Stem Cell Derived Cardiac Cells Recapitulate in vitro Human Cardiac Pathophysiology. Frontiers in bioengineering and biotechnology. Laussane: Frontiers Media S.A., 2020, vol. 8, June 2019, p. 1-19. ISSN 2296-4185. Available from: https://dx.doi.org/10.3389/fbioe.2020.00535.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name DMD Pluripotent Stem Cell Derived Cardiac Cells Recapitulate in vitro Human Cardiac Pathophysiology
Authors JELÍNKOVÁ, Šárka (203 Czech Republic, belonging to the institution), Aleksandra VILOTIĆ (688 Serbia, belonging to the institution), Jan PŘIBYL (203 Czech Republic, belonging to the institution), Franck AIMOND (250 France), Anton SALYKIN (643 Russian Federation, belonging to the institution), Ivana AĆIMOVIĆ (688 Serbia, belonging to the institution), Martin PEŠL (203 Czech Republic), Guido CALUORI (380 Italy, belonging to the institution), Šimon KLIMOVIČ (203 Czech Republic, belonging to the institution), Tomáš URBAN (203 Czech Republic, belonging to the institution), Hana DOBROVOLNÁ (203 Czech Republic), Vladimír SOŠKA (203 Czech Republic), Petr SKLÁDAL (203 Czech Republic), Alain LACAMPAGNE (250 France), Petr DVOŘÁK (203 Czech Republic, belonging to the institution), Albano C. MELI (250 France) and Vladimír ROTREKL (203 Czech Republic, guarantor, belonging to the institution).
Edition Frontiers in bioengineering and biotechnology, Laussane, Frontiers Media S.A. 2020, 2296-4185.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30401 Health-related biotechnology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.890
RIV identification code RIV/00216224:14110/20:00116091
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fbioe.2020.00535
UT WoS 000548398600001
Keywords in English duchenne muscular dystrophy; DMD; human pluripotent stem cells; cardiomyocytes; intracellular calcium; excitation-contraction coupling; adrenergic response; cardiomyocyte death
Tags 14110115, 14110116, 14110513, CF NANO, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 7/2/2022 10:36.
Abstract
Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by the lack of functional dystrophin. DMD is associated with progressive dilated cardiomyopathy, eventually leading to heart failure as the main cause of death in DMD patients. Although several molecular mechanisms leading to the DMD cardiomyocyte (DMD-CM) death were described, mostly in mouse model, no suitable human CM model was until recently available together with proper clarification of the DMD-CM phenotype and delay in cardiac symptoms manifestation. We obtained several independent dystrophin-deficient human pluripotent stem cell (hPSC) lines from DMD patients and CRISPR/Cas9-generated DMD gene mutation. We differentiated DMD-hPSC into cardiac cells (CC) creating a human DMD-CC disease model. We observed that mutation-carrying cells were less prone to differentiate into CCs. DMD-CCs demonstrated an enhanced cell death rate in time. Furthermore, ion channel expression was altered in terms of potassium (Kir2.1 overexpression) and calcium handling (dihydropyridine receptor overexpression). DMD-CCs exhibited increased time of calcium transient rising compared to aged-matched control, suggesting mishandling of calcium release. We observed mechanical impairment (hypocontractility), bradycardia, increased heart rate variability, and blunted beta-adrenergic response connected with remodeling of beta-adrenergic receptors expression in DMD-CCs. Overall, these results indicated that our DMD-CC models are functionally affected by dystrophin-deficiency associated and recapitulate functional defects and cardiac wasting observed in the disease. It offers an accurate tool to study human cardiomyopathy progression and test therapiesin vitro.
Links
EF16_013/0001776, research and development projectName: Česká infrastruktura pro integrativní strukturní biologii pro lidské zdraví
LM2018127, research and development projectName: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
ROZV/28/LF12/2020, interní kód MUName: Analýza arytmogenicity a kardiotoxicity vybraných plicních léčiv na kardiomyocytech diferencovaných z kmenových buněk
Investor: Ministry of Education, Youth and Sports of the CR, Internal development projects
2SGA2744, interní kód MUName: CARDIOSTEM (Acronym: CARDIOSTEM)
Investor: South-Moravian Region, Incoming grants
7AMB13FR011, research and development projectName: Přeprogramování somatických buněk darovaných pacienty s dědičnou Duchennovou svalovou dystrofií do kardiomyocytů - nahlédnutí do molekulární podstaty patologických dějů u dilatační kardiomyopatie nemocných DMD (Acronym: DUCHENSTEM)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 14/5/2024 16:28